Q-omics provides the consensus-scored NRP2 profile across patient tissues and cancer cell-line models. NRP2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NRP2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NRP2 protein abundance shows 20,905 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight MESO, KIRC, and COAD as cancer lineages where NRP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRP2 survival associations across molecular data types. NRP2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRP2 RNA expression–survival associations across cancer types. High NRP2 expression shows unfavorable associations in MESO, KIRP, BLCA, PAAD and STAD, but favorable associations in THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NRP2 RNA expression.
This table summarizes NRP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NRP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRP2 shows lower tumor expression in BLCA and higher tumor expression in KIRC, THCA, HNSC, CHOL and LIHC. The KIRC box plot shows higher NRP2 RNA expression in tumor versus normal tissue (log2 FC = +2.124, t-test p < 0.001).
This table shows molecular features associated with NRP2 in patient tissues and cancer cell lines. In patient samples, NRP2 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NRP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
